Abrogating Phosphorylation of eIF4B Is Required for EGFR and mTOR Inhibitor Synergy in Triple-Negative Breast Cancer

Breast Cancer Research and Treatment - Netherlands
doi 10.1007/s10549-014-3102-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Triple-Negative Breast Cancer

2018English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

Nano-Targeted Delivery of Rad6/Translesion Synthesis Inhibitor for Triple Negative Breast Cancer Therapy

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

Synthetic Lethal Interactions Between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells

PLoS ONE
Multidisciplinary
2012English

Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2015English

Aminoflavone-Loaded EGFR-targeted Unimolecular Micelle Nanoparticles Exhibit Anti-Cancer Effects in Triple Negative Breast Cancer

Biomaterials
Mechanics of MaterialsBiophysicsBiomaterialsBioengineeringCompositesNanoscienceNanotechnologyCeramics
2016English

T‑cadherin Is Associated With Prognosis in Triple‑negative Breast Cancer

Oncology Letters
Cancer ResearchOncology
2017English

Brachyury, a Vaccine Target, Is Overexpressed in Triple-Negative Breast Cancer

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2016English

Preclinical Evaluation of a Novel Triple-Acting PIM/PI3K/mTOR Inhibitor, IBL-302, in Breast Cancer

Oncogene
Cancer ResearchGeneticsMolecular Biology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy